Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC, Hong DS. Gounder MM, et al. Among authors: doebele rc. J Clin Oncol. 2023 Mar 20;41(9):1714-1724. doi: 10.1200/JCO.22.01285. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669146 Free PMC article. Clinical Trial.
Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
Elkrief A, Odintsov I, Markov V, Caeser R, Sobczuk P, Tischfield SE, Bhanot U, Vanderbilt CM, Cheng EH, Drilon A, Riely GJ, Lockwood WW, de Stanchina E, Tirunagaru VG, Doebele RC, Quintanal-Villalonga Á, Rudin CM, Somwar R, Ladanyi M. Elkrief A, et al. Among authors: doebele rc. J Thorac Oncol. 2023 Sep;18(9):1165-1183. doi: 10.1016/j.jtho.2023.05.007. Epub 2023 May 13. J Thorac Oncol. 2023. PMID: 37182602
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L, Elliott A, Le AT, Estrada-Bernal A, Doebele RC, Lou E, Borghaei H, Demeure MJ, Kurzrock R, Reuss JE, Ou SI, Braxton DR, Thomas CA, Darabi S, Korn WM, El-Deiry WS, Liu SV. Schubert L, et al. Among authors: doebele rc. Front Oncol. 2023 Apr 24;13:1115405. doi: 10.3389/fonc.2023.1115405. eCollection 2023. Front Oncol. 2023. PMID: 37168365 Free PMC article.
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, Bergman B, Kristenson L, Thorén FB, Le A, Doebele RC, Van den Eynden J, Palmer RH, Hallberg B. Chuang TP, et al. Among authors: doebele rc. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2216479120. doi: 10.1073/pnas.2216479120. Epub 2023 Feb 15. Proc Natl Acad Sci U S A. 2023. PMID: 36791109 Free PMC article.
150 results